Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59ec37318623e42970ac9b8cc9e49559 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b01dcd61775e996fac631d4b10c4e87f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e3b4f2ef8f062dcde3a2b7cd81748472 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-0071 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0663 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y114-14001 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-0042 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0775 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate |
2020-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a0085ef1921c015f1453a3ab0ff69ce http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34b32cb3c91966ce52ae73a5cfaf3db5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab7ce4afd425d9e4936d4cd1bfa61119 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5aeefa84a900452d48c596c662d5d516 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd44893714b5041463767918265a7faa |
publicationDate |
2022-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-4045633-A1 |
titleOfInvention |
Genetically modified human stem cell expressing a mutant human cytochrome p450 2b6 protein and use thereof in the treatment of cancer |
abstract |
The present invention relates to a genetically modified human stem cell, in which said human stem cell comprises an exogenous nucleic acid comprising a region encoding a fusion protein comprising a mutant human cytochrome P450 2B6 (CYP2B6*) protein of SEQ ID No. 1 or a variant or fragment thereof and an NADPH-cytochrome P450 reductase protein of SEQ ID No. 2 or a variant or fragment thereof, functionally bound to a promoter, said exogenous nucleic acid having been integrated into chromosome 17 of said human stem cell. The invention also relates to the use of said cell for preventing and/or treating cancer and/or associated metastases, particularly solid tumours, and in particular hepatocellular carcinomas, and/or cancer recurrences and/or associated metastases. |
priorityDate |
2019-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |